- Home
- LEGN vs ELVN Comparison
LEGN vs ELVN Comparison
Compare LEGN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGN | ELVN |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LEGN | ELVN |
|---|---|---|
| Price | $19.18 | $41.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $45.62 | ★ $73.92 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.73 | N/A |
| Revenue Next Year | $23.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.24 | $14.79 |
| 52 Week High | $37.50 | $62.32 |
Technical Indicators
Market Signals| Indicator | LEGN | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 39.47 |
| Support Level | $17.08 | $37.77 |
| Resistance Level | $19.92 | $43.05 |
| Average True Range (ATR) | 0.86 | 1.84 |
| MACD | 0.11 | 0.57 |
| Stochastic Oscillator | 68.43 | 50.69 |
Price Performance
Historical ComparisonAbout LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.